FierceBiotech 13 avr. 2026 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 28 févr. 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival